|
WO2005019255A1
(en)
*
|
2003-08-25 |
2005-03-03 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
US7611847B2
(en)
|
2005-06-01 |
2009-11-03 |
Agency For Science, Technology And Research |
Method for identifying an intestinal phenotype
|
|
EP1989529A4
(de)
|
2006-02-13 |
2010-09-01 |
Agency Science Tech & Res |
Verfahren zur bearbeitung einer biologischen und/oder chemischen probe
|
|
JP4987885B2
(ja)
|
2006-03-09 |
2012-07-25 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
小滴中で反応を行うための装置及びその使用方法
|
|
EP1996613B1
(de)
|
2006-03-20 |
2014-04-30 |
Technische Universität München |
Muteine von tränenlipocalin mit affinität für den t-zellen-corezeptor cd4
|
|
DE602007009995D1
(de)
|
2006-08-01 |
2010-12-02 |
Pieris Ag |
Muteine von tearlipocalin und verfahren zu deren gewinnung
|
|
CN101516907B
(zh)
*
|
2006-08-01 |
2015-08-26 |
皮里斯股份公司 |
泪液脂质运载蛋白的突变蛋白及其获得方法
|
|
WO2008063135A1
(en)
|
2006-11-24 |
2008-05-29 |
Agency For Science, Technology And Research |
Apparatus for processing a sample in a liquid droplet and method of using the same
|
|
US9874501B2
(en)
|
2006-11-24 |
2018-01-23 |
Curiox Biosystems Pte Ltd. |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
EP2146740A4
(de)
|
2007-04-13 |
2010-05-26 |
Agency Science Tech & Res |
Verfahren zur kontrolle der tumorigenese und diagnose des risikos
|
|
JP2011504462A
(ja)
|
2007-11-02 |
2011-02-10 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
腫瘍の予防および治療のための方法および化合物
|
|
WO2013114217A1
(en)
|
2012-02-05 |
2013-08-08 |
Curiox Biosystems Pte Ltd. |
Array plates and methods for making and using same
|
|
US10725020B2
(en)
|
2007-11-14 |
2020-07-28 |
Curiox Biosystems Pte Ltd. |
High throughput miniaturized assay system and methods
|
|
TW200944231A
(en)
|
2007-11-30 |
2009-11-01 |
Glaxo Group Ltd |
Antigen-binding constructs
|
|
EP2245054B1
(de)
*
|
2008-01-30 |
2018-11-28 |
Pieris Pharmaceuticals GmbH |
Muteine von tränen-lipocalin mit affinität zur humanen c-met-rezeptor-tyrosinkinase und verfahren zu deren gewinnung
|
|
US20090274623A1
(en)
*
|
2008-01-30 |
2009-11-05 |
General Electric Company |
In vivo imaging agents for met receptor tyrosine kinase
|
|
WO2009132351A2
(en)
*
|
2008-04-25 |
2009-10-29 |
University Of Medicine And Dentistry Of New Jersey |
Anti-sense microrna expression vectors
|
|
US9102920B2
(en)
|
2008-05-06 |
2015-08-11 |
Agency For Science, Technology And Research |
Method of effecting de-differentiation of a cell
|
|
PE20091964A1
(es)
|
2008-05-06 |
2010-01-09 |
Glaxo Group Ltd |
Encapsulacion de agentes biologicamente activos
|
|
US8420051B2
(en)
|
2008-06-24 |
2013-04-16 |
Technische Universitaet Meunchen |
Muteins of hNGAL and related proteins with affinity for a given target
|
|
JP2010074915A
(ja)
*
|
2008-09-17 |
2010-04-02 |
Jtekt Corp |
モータ制御装置及び電動パワーステアリング装置
|
|
WO2010044752A1
(en)
|
2008-10-13 |
2010-04-22 |
Agency For Science, Technology And Research |
Amphiphilic polymers and nanocrystals coated therewith
|
|
DK2189539T4
(en)
|
2008-11-21 |
2018-09-17 |
Chimera Biotec Gmbh |
Conjugate complexes for analyte detection
|
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
|
CA2753287A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
EP2401296A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Multivalente und/oder multispezifische rankl-bindende konstrukte
|
|
US20110305693A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Anitigen-binding constructs
|
|
US8784752B2
(en)
|
2009-04-17 |
2014-07-22 |
Curiox Biosystems Pte Ltd |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
EP2452195A4
(de)
|
2009-07-07 |
2012-12-05 |
Agency Science Tech & Res |
Verfahren zur identifikation eines paares von verbindungspartnern
|
|
EP2459053A2
(de)
|
2009-07-28 |
2012-06-06 |
F. Hoffmann-La Roche AG |
Nicht invasives optisches in-vivo-bildgebungsverfahren
|
|
BR112012002709A2
(pt)
|
2009-08-05 |
2019-04-30 |
Pieris Ag |
formulações de liberação controlada de muteínas de lipocalina
|
|
BR112012013662B1
(pt)
|
2009-12-07 |
2022-08-02 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
|
|
US9689801B2
(en)
|
2009-12-22 |
2017-06-27 |
Agency For Science, Technology And Research |
SERS-based analyte detection
|
|
CA2787070A1
(en)
|
2010-01-28 |
2011-08-04 |
Ian Kirby |
Cd127 binding proteins
|
|
KR101341640B1
(ko)
*
|
2010-02-05 |
2013-12-16 |
한국전자통신연구원 |
단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
|
|
CN103119054B
(zh)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
RU2012148816A
(ru)
|
2010-05-07 |
2014-06-20 |
Ф. Хоффманн-Ля Рош Аг |
Метод диагностики для определения клеток ex vivo
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
AU2011263786B2
(en)
|
2010-06-08 |
2014-11-13 |
Astrazeneca Ab |
Tear lipocalin muteins binding IL-4 R alpha
|
|
WO2012011877A2
(en)
|
2010-07-23 |
2012-01-26 |
Curiox Biosystems Pte Ltd |
Apparatus and method for multiple reactions in small volumes
|
|
AU2011290751B2
(en)
|
2010-08-16 |
2015-08-13 |
Pieris Ag |
Binding proteins for Hepcidin
|
|
WO2012032069A1
(en)
|
2010-09-07 |
2012-03-15 |
Pieris Ag |
Recombinant bacterial lipocalin blc and uses thereof
|
|
KR20130096731A
(ko)
*
|
2010-09-08 |
2013-08-30 |
할로자임, 아이엔씨 |
조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
|
|
CA2817779C
(en)
|
2010-11-15 |
2019-02-19 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
MX351887B
(es)
|
2010-11-23 |
2017-11-01 |
Glaxo Group Ltd |
Proteinas de union a antigeno para oncostatina m (osm).
|
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
|
US9221885B2
(en)
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
|
WO2012136685A1
(en)
|
2011-04-04 |
2012-10-11 |
Pieris Ag |
Methods and compositions for anti-vegf and anti-c-met therapy
|
|
RU2623161C2
(ru)
|
2011-04-15 |
2017-06-22 |
Компуджен Лтд. |
Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
|
|
EP2714737A1
(de)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17)-bindende proteine
|
|
RU2605595C2
(ru)
|
2011-06-13 |
2016-12-20 |
СиЭсЭл Лимитид |
Антитела против g-csfr и их применение
|
|
WO2013048986A1
(en)
|
2011-09-26 |
2013-04-04 |
Knoa Software, Inc. |
Method, system and program product for allocation and/or prioritization of electronic resources
|
|
JP2015504413A
(ja)
|
2011-10-28 |
2015-02-12 |
パトリス リミテッド |
Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
|
|
DK2791684T3
(da)
|
2011-12-12 |
2017-11-27 |
Pieris Pharmaceuticals Gmbh |
Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering
|
|
EP3453400B1
(de)
|
2011-12-13 |
2021-01-20 |
Pieris Pharmaceuticals GmbH |
Verfahren zur vorbeugung oder behandlung bestimmter erkrankungen durch hemmung der bindung von il-4 und/oder il-13 an ihre jeweiligen rezeptoren
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
AP2014007792A0
(en)
|
2012-01-09 |
2014-07-31 |
Pieris Ag |
Methods for preventing, treating or diagnosing disorders
|
|
US9758554B2
(en)
|
2012-01-31 |
2017-09-12 |
Technische Universitaet Muenchen |
Muteins of α1m lipocalin and method of production therefor
|
|
SG10201708562VA
(en)
|
2012-02-13 |
2017-12-28 |
Agency Science Tech & Res |
IL-1β Neutralizing Human Monoclonal Antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
WO2013189521A1
(en)
|
2012-06-19 |
2013-12-27 |
Waclawczyk Simon |
Method of generating cells of hepatocyte phenotype
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(zh)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
EP2920202B1
(de)
|
2012-11-19 |
2018-08-29 |
Pieris Pharmaceuticals GmbH |
Neue spezifisch bindende polypeptide und ihre verwendung
|
|
WO2014140210A1
(en)
|
2013-03-14 |
2014-09-18 |
Pieris Ag |
Novel binding proteins for pcsk9
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US9557318B2
(en)
|
2013-07-09 |
2017-01-31 |
Curiox Biosystems Pte Ltd. |
Array plates for washing samples
|
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
|
TR201900665T4
(tr)
|
2013-11-28 |
2019-02-21 |
B Creative Sweden Ab |
Diyabetik nefropatinin tedavi yöntemi.
|
|
CN105979965B
(zh)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
LU92409B1
(en)
|
2014-03-21 |
2015-09-22 |
Philipps Universit T Marburg |
Means and methods for itaconic acid production
|
|
EP3145945B1
(de)
|
2014-05-22 |
2020-07-15 |
Pieris Pharmaceuticals GmbH |
Neuartige polypeptide mit spezifischer bindung und verwendungen davon
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
ES2788979T3
(es)
|
2014-11-14 |
2020-10-23 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
|
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
|
WO2016113203A1
(en)
|
2015-01-12 |
2016-07-21 |
Pieris Ag |
Engineered t cells and uses therefor
|
|
SG11201705278QA
(en)
|
2015-01-28 |
2017-07-28 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for angiogenesis
|
|
EP3064507A1
(de)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon
|
|
RU2727165C2
(ru)
|
2015-05-04 |
2020-07-21 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
PH12017501583B1
(en)
|
2015-05-04 |
2023-01-20 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for cd137
|
|
DK3298030T5
(en)
|
2015-05-18 |
2024-10-07 |
Pieris Pharmaceuticals Gmbh |
Anti-cancerfusionspolypeptid
|
|
EP3298029A1
(de)
|
2015-05-18 |
2018-03-28 |
Pieris Pharmaceuticals GmbH |
Muteine von menschlichem lipocalin 2 mit affinität für glypican-3 (gpc3)
|
|
US10545139B2
(en)
|
2015-06-16 |
2020-01-28 |
Curiox Biosystems Pte Ltd. |
Methods and devices for performing biological assays using magnetic components
|
|
EP3722314A1
(de)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
|
EP3115066A1
(de)
|
2015-07-07 |
2017-01-11 |
Technische Universität München |
Neuartige psma-spezifische bindeproteine
|
|
MX2018000447A
(es)
|
2015-07-15 |
2018-08-15 |
Pieris Pharmaceuticals Gmbh |
Novedosas proteinas especificas para lag-3.
|
|
BR112018000366A2
(pt)
|
2015-08-07 |
2018-09-11 |
Pieris Pharmaceuticals Gmbh |
polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
PE20181349A1
(es)
|
2015-10-07 |
2018-08-22 |
Hoffmann La Roche |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
|
|
AU2016361462B2
(en)
|
2015-11-27 |
2023-09-21 |
Csl Limited |
CD131 binding proteins and uses thereof
|
|
US10703810B2
(en)
|
2015-11-30 |
2020-07-07 |
Pieris Australia Pty Ltd. |
Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
|
PE20190115A1
(es)
|
2016-04-15 |
2019-01-16 |
Immunext Inc |
Anticuerpos vista antihumanos y su uso
|
|
EP3455254B1
(de)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und einem tenascin-bindungsteil
|
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
JP7125400B2
(ja)
|
2016-12-19 |
2022-08-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
CA3047070A1
(en)
|
2017-01-03 |
2018-07-12 |
F.Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
JP7225116B2
(ja)
*
|
2017-01-18 |
2023-02-20 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
WO2018178076A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110402255B
(zh)
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
EP4280260A3
(de)
|
2017-04-05 |
2024-03-06 |
Curiox Biosystems Pte Ltd. |
Verfahren, vorrichtungen und einrichtung zum waschen von proben auf arrayplatten
|
|
KR102755742B1
(ko)
|
2017-09-11 |
2025-01-15 |
모나쉬 유니버시티 |
인간 트롬빈 수용체 par4 결합 단백질
|
|
KR102715492B1
(ko)
|
2017-10-18 |
2024-10-11 |
씨에스엘 리미티드 |
인간 혈청 알부민 변이체 및 이의 용도
|
|
PE20210844A1
(es)
|
2017-11-01 |
2021-05-10 |
Hoffmann La Roche |
Contorsbodies 2 + biespecificos
|
|
EP3704155A2
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit gezielten ox40-agonisten
|
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
PL3765489T3
(pl)
|
2018-03-13 |
2025-02-10 |
F. Hoffmann-La Roche Ag |
Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
|
|
US12281160B2
(en)
|
2018-03-23 |
2025-04-22 |
Csl Limited |
Method of treating asthma
|
|
CR20200459A
(es)
|
2018-04-13 |
2020-11-11 |
Hoffmann La Roche |
Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
|
|
WO2019243564A1
(en)
|
2018-06-21 |
2019-12-26 |
Technische Universitaet Muenchen |
Hepatitis b and/or hepatitis d-permissive cells and animals
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
RS64343B9
(sr)
|
2018-07-31 |
2023-11-30 |
Pieris Pharmaceuticals Gmbh |
Novi fuzioni protein specifičan za cd137 i pd-l1
|
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
|
US11242396B2
(en)
|
2018-10-01 |
2022-02-08 |
Hoffmann-La Roche Inc. |
Bispecific antigen binding molecules comprising anti-FAP clone 212
|
|
US20200223925A1
(en)
|
2018-12-21 |
2020-07-16 |
Hoffmann-La Roche Inc. |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
CR20210326A
(es)
|
2018-12-21 |
2021-09-10 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
|
|
JP7476219B2
(ja)
|
2019-02-26 |
2024-04-30 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
CN113939307A
(zh)
|
2019-03-29 |
2022-01-14 |
皮里斯制药有限公司 |
脂质运载蛋白突变蛋白的吸入施用
|
|
EP3946415A1
(de)
|
2019-03-29 |
2022-02-09 |
Astrazeneca AB |
Lipocalinmutein zur behandlung von asthma
|
|
CN113677403B
(zh)
|
2019-04-12 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
|
BR112021026293A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
|
|
EP3990492A1
(de)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Neuartige icos-antikörper und tumorspezifische antigenbindende moleküle damit
|
|
AU2020379176A1
(en)
|
2019-11-04 |
2022-06-09 |
Pieris Pharmaceuticals Gmbh |
HER2/4-1BB bispecific fusion proteins for the treatment of cancer
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
CN115768475A
(zh)
|
2020-06-04 |
2023-03-07 |
Csl创新私人有限公司 |
治疗或预防急性呼吸窘迫综合征的方法
|
|
CA3177098A1
(en)
|
2020-06-05 |
2021-12-09 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
|
CR20220627A
(es)
|
2020-06-23 |
2023-02-17 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
|
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
|
MX2023007174A
(es)
|
2020-12-18 |
2023-09-08 |
Astrazeneca Ab |
Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma.
|
|
CN116829598A
(zh)
|
2021-01-06 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
CN117355319A
(zh)
|
2021-03-23 |
2024-01-05 |
皮里斯制药有限责任公司 |
用于癌症治疗的her2/4-1bb双特异性融合蛋白
|
|
AU2022253567A1
(en)
|
2021-04-08 |
2023-11-23 |
Pieris Pharmaceuticals Gmbh |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
AR127728A1
(es)
|
2021-11-19 |
2024-02-21 |
Pieris Pharmaceuticals Gmbh |
Nueva proteína de fusión específica para ox40 y pd-l1
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
EP4499229A1
(de)
|
2022-03-28 |
2025-02-05 |
F. Hoffmann-La Roche AG |
Interferon-gamma-varianten und antigenbindende moleküle damit
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
EP4587122A1
(de)
|
2022-09-15 |
2025-07-23 |
Avidicure IP B.V. |
Multispezifische antigenbindende proteine zur stimulierung von nk-zellen und verwendung davon
|
|
PE20251544A1
(es)
|
2022-09-21 |
2025-06-05 |
Seagen Inc |
Nueva proteina de fusion especifica para cd137 y cd228
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
CN120835901A
(zh)
|
2023-03-13 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
|
|
EP4720124A1
(de)
|
2023-05-24 |
2026-04-08 |
Mozart Therapeutics, Inc. |
Cd8-spezifische bindungsproteine und verfahren zur verwendung davon
|
|
TW202504918A
(zh)
|
2023-06-01 |
2025-02-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ｂｃｍａ及ｃｄ２８的雙特異性抗體
|
|
EP4720121A1
(de)
|
2023-06-01 |
2026-04-08 |
F. Hoffmann-La Roche AG |
Immunstimulierende antigenbindende moleküle, die spezifisch an bcma binden
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
EP4739706A1
(de)
|
2023-07-05 |
2026-05-13 |
CSL Innovation Pty Ltd |
Verfahren zur behandlung oder prävention einer komplikation von sichelzellanämie
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025191139A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of her2-specific antigen binding proteins and cytokines
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2026087748A1
(en)
|
2024-10-24 |
2026-04-30 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
|
|
WO2026087747A1
(en)
|
2024-10-24 |
2026-04-30 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
|
|
WO2026093923A1
(en)
|
2024-10-29 |
2026-05-07 |
Csl Behring Ag |
Method for detection of a plasma protein
|
|
GB202417141D0
(en)
|
2024-11-21 |
2025-01-08 |
Cambridge Entpr Ltd |
In vitro screening system
|